Wells Fargo analyst Larry Biegelsen lowered the firm’s price target on Medtronic (MDT) to $98 from $106 and keeps an Overweight rating on the shares after the company reported a Q2 revenue beat. Cardiovascular, neuro, and diabetes drove the beat, Wells adds. Medtronic raised FY25 guide to 4.75%-5.0%, and looking to FY26, the firm continues to believe EPS growth could outpace top line.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic Reports Strong Q2 2025 Results, Raises Guidance
- Trump Trade: President-elect seeks to kill Biden fuel-efficiency rules
- Morning Movers: Walmart jumps following quarterly results
- MDT Earnings: Medtronic Beats Q2 Expectations, Boosts FY25 Guidance
- Medtronic sees Q3 adjusted EPS $1.35-$1.37, consensus $1.60